Personalis’ (PSNL) “Buy” Rating Reiterated at HC Wainwright

Personalis (NASDAQ:PSNL)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a research note issued on Wednesday,Benzinga reports. They presently have a $11.00 target price on the stock. HC Wainwright’s price target suggests a potential upside of 83.95% from the company’s previous close.

Separately, Needham & Company LLC restated a “buy” rating and set a $7.25 price target on shares of Personalis in a research note on Friday, December 20th.

Personalis Stock Performance

PSNL opened at $5.98 on Wednesday. Personalis has a 1 year low of $1.12 and a 1 year high of $7.20. The company’s 50 day simple moving average is $4.68 and its 200 day simple moving average is $4.31. The stock has a market capitalization of $422.48 million, a PE ratio of -3.56 and a beta of 1.75.

Personalis (NASDAQ:PSNL) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.31). The company had revenue of $25.71 million during the quarter, compared to analyst estimates of $20.67 million. Personalis had a negative net margin of 104.52% and a negative return on equity of 66.07%. During the same quarter last year, the business earned ($0.51) EPS. As a group, sell-side analysts expect that Personalis will post -1.41 earnings per share for the current fiscal year.

Institutional Trading of Personalis

A number of institutional investors have recently added to or reduced their stakes in PSNL. nVerses Capital LLC acquired a new position in shares of Personalis during the third quarter worth about $40,000. IQ EQ FUND MANAGEMENT IRELAND Ltd raised its holdings in shares of Personalis by 42.5% during the 3rd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 15,103 shares of the company’s stock valued at $81,000 after buying an additional 4,504 shares during the period. International Assets Investment Management LLC lifted its position in Personalis by 438.0% during the 3rd quarter. International Assets Investment Management LLC now owns 20,982 shares of the company’s stock worth $113,000 after acquiring an additional 17,082 shares in the last quarter. Quantbot Technologies LP purchased a new position in Personalis in the 3rd quarter worth approximately $210,000. Finally, Barclays PLC grew its position in Personalis by 45.4% in the third quarter. Barclays PLC now owns 65,468 shares of the company’s stock valued at $352,000 after acquiring an additional 20,444 shares in the last quarter. 61.91% of the stock is owned by hedge funds and other institutional investors.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.